Marquette Intellectual Property Law Review

COPYRIGHT TV Trade Media, Inc.
COPYRIGHT GALE, Cengage Learning. All rights reserved.

COPYRIGHT GALE, Cengage Learning. All rights reserved

from January 2007
Last Number: June 2020

Marquette University Law School
ISSN 1092-5899


Cantidad de documentos en esta fuente: 205

January 01, 2012

  • A state-by-state analysis of inevitable disclosure: a need for uniformity and a workable standard.

  • Environmental initiative and the role of the USPTO'S green technology pilot program.

    • June 22, 2012

  • Contract + tort = property: the trade secret illustration.

  • Using intellectual property rights to create value in the coffee industry.

  • God in the machine: encryption algorithms and the abstract exemption to patentability.

  • Intellectual property and Asian values.

  • Intellectual property and Asian values.

  • Structural uncertainty: understanding the Federal Circuit's lead compound analysis.

  • Reviewing the (shrinking) principle of Trademark Exhaustion in the European Union (ten years later).

  • What good is fame if you can't be famous in your own right? Publicity right woes of the almost famous.

    • January 01, 2013

  • Beneficiaries of misconduct: a direct approach to IT theft.

  • The end of ownership?

  • Free fashion.

  • The immorality of strict liability in copyright.

  • The National Institutes of Health, patents, and the public interest: an expanded rationale of justice Breyer's dissent in Stanford v. Roche.

  • Reverse engineering IP.

    • June 22, 2013

  • Federal circuit v. ninth circuit: a split over the conflicting approaches to DMCA section 1201.

    • January 01, 2014

  • The increasing importance of biologics-based drugs in pharmaceutical pipelines.

  • Need for new IP approaches to facilitate collaborative (academic-industrial) drug development.

  • New business models to find cures and lower healthcare costs: a role for drug repurposing.

  • Repurposing & collaborative drug development for rare diseases.

  • The future of clinical trials: more transparency and pharmacogenomics.

  • Implications of genomics advances for drug discovery, clinical therapies, & rare disease research.

  • Intellectual property rights (IPR) in collaborative drug development in the EU: helping a European public-private partnership deliver - the need for a flexible approach to IPR.

  • Diagnostic patents at the Supreme Court.

  • A new framework for assessing clinical data transparency initiatives.

  • The new era of biologic regulation and patenting under the America Invents Act.

  • How media got the biggest bite of (the) Apple: a look at the media misperception in the Apple-Samsung case.

    • June 22, 2014

  • One view of compulsory licensing: comparative perspectives from India and Canada.

  • Searching for an out: Rojadirecta, myVidster, and the knowledge components of the information location tool exemption of s. 512(d).

  • Likelihood of destruction - restructuring the trademark dilution by blurring factors in the Trademark Dilution Revision Act of 2006.

    • January 01, 2015

  • The intensifying national interest in patent litigation.

  • The EU trademark reform package - (too) bold a step ahead or back to status quo?

  • Brands, morality and public policy: some reflections on the ban on registration of controversial trademarks.

  • Can the PTO find its way with Jesus?

  • A presidential remedy under administrative control - why section 337(j) should be repealed.

  • Notice and supplemental registration: why the Copyright Office must update its policies surrounding author notice.

  • The end of the 'wild west' for software patents - does the Patents Act 2013 change New Zealand's treatment of software patents from permissive to restrictive?

    • June 22, 2015

  • Product hopping 2.0: getting the FDA to yank your original license beats stacking patents.

  • Copyrights without limits: the undefeatable right of access control under section 1201(a) of the Digital Millennium Copyright Act.

  • Mylan v. Warner Chilcott: a study in pharmaceutical product hopping.

  • Now is that what I call music? Post-modern classical music and copyright law.

  • Public K-12 teachers creation of nontraditional educational works: to rely on the teacher exception or explore other options?

  • Hart-Scott-Rodino & Chevron step zero: can the FTC target the pharmaceutical industry?

    • January 01, 2016

  • Punitive damage and attorney fee awards in trade secret cases.

  • iHeartgeo-fencing? The section 114 exemption that illustrates why full sound recording rights are the sine qua non for a vibrant music industry.

  • EU directive proposal: trade secrets.

  • In pursuit of patent quality (and reflections on reification).

  • Under seal but not under law: In re City of Houston's effect on municipal insignias.

  • Collegiate athletes and the right to their marks.